Crossmark

The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study

Crossref DOI link: https://doi.org/10.1186/s12967-023-04391-1

Published Online: 2023-08-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dummer, Reinhard

Welti, Michèle

Ramelyte, Egle http://orcid.org/0000-0001-8262-8608
License Information

Text and Data Mining valid from 2023-08-05

Version of Record valid from 2023-08-05
More Information

Article History

Received: 19 July 2023

Accepted: 25 July 2023

First Online: 5 August 2023

Declarations

:

: Not applicable.

: Not applicable.

: R. Dummer has intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME outside the submitted work. M. Welti and E. Ramelyte have no conflicts of interest regarding this Commentary.

Document is current

Any future updates will be listed below